Delafloxacin
- Generic Name
- Delafloxacin
- Brand Names
- Baxdela, Quofenix
- Drug Type
- Small Molecule
- Chemical Formula
- C18H12ClF3N4O4
- CAS Number
- 189279-58-1
- Unique Ingredient Identifier
- 6315412YVF
- Background
Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and...
- Indication
Delafloxacin is indicated for the treatment of acute bacterial skin and skin structure infections caused by the Gram-positive organisms Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Strept...
- Associated Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP)
- Associated Therapies
- -
A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06612255
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Menarini Group
- Target Recruit Count
- 268
- Registration Number
- NCT04042077
- Locations
- 🇮🇹
Hospital Agostino Gemelli, Roma, Italy
Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03534622
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 860
- Registration Number
- NCT02679573
- Locations
- 🇺🇦
Melinta 306 Study Site, Zhytomyr, Ukraine
Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02505997
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02245243
- Locations
- 🇺🇸
Melinta 112 Study Site, Orlando, Florida, United States
Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT02015637
- Locations
- 🇺🇸
Melinta 304 Study, Erie, Pennsylvania, United States
🇺🇸Melinta 304 Study Site, Seattle, Washington, United States
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 850
- Registration Number
- NCT01984684
- Locations
- 🇨🇳
Melinta 303 Study Site, Zhonghe, Taiwan
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 660
- Registration Number
- NCT01811732
- Locations
- 🇺🇦
Melinta Investigational Site, Zaporizhzhia, Ukraine
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
- Conditions
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 256
- Registration Number
- NCT01283581
- Locations
- 🇺🇸
University of South Alabama Medical Center, Mobile, Alabama, United States
🇺🇸Southbay Pharma Research, Buena Park, California, United States
🇺🇸Drug Research and Analysis Corp, Montgomery, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.